Edmonton, AB, Canada – Fedora Pharmaceuticals, Inc., a private biotechnology company, announced the creation of a board of directors and the appointments of Leonard E. Post and Ronald W. Odynski as directors. [break]
Dr. Post has more than 30 years of experience in all stages of pharmaceutical and biotechnology company R&D from early drug discovery through clinical development and FDA approval. Dr. Post is currently the chief scientific officer of BioMarin Pharmaceuticals. In addition, he sits on the Boards of Directors of Altiris Therapeutics and Orphagen Pharmaceuticals, two private biotechnology companies and Viralytics, a public
biotechnology company listed on the Australian Stock Exchange.
Prior to joining BioMarin, Dr. Post held various senior research positions at LEAD Therapeutics, Onyx Pharmaceuticals and Parke - October 31, 2012, Edmonton, AB, Canada – Fedora Pharmaceuticals, Inc., a private biotechnology company, announced the creation of a board of directors and the appointments of Leonard E. Post and Ronald W. Odynski as directors.
Article continues below
]
Dr. Post has more than 30 years of experience in all stages of pharmaceutical and biotechnology company R&D from early drug discovery through clinical development and FDA approval. Dr. Post is currently the chief scientific officer of BioMarin Pharmaceuticals. In addition, he sits on the Boards of Directors of Altiris Therapeutics and Orphagen Pharmaceuticals, two private biotechnology companies and Viralytics, a public
biotechnology company listed on the Australian Stock Exchange.
Prior to joining BioMarin, Dr. Post held various senior research positions at LEAD Therapeutics, Onyx Pharmaceuticals and Parke-Davis Pharmaceuticals. He received a Bachelor of Science in chemistry from the University of Michigan and a doctorate in biochemistry from
the University of Wisconsin, after which he performed a postdoctoral fellowship in virology at the University of Chicago with Dr. Bernard Roizman.
Mr. Odynski currently serves as the managing partner of Ogilvie LLP and provides general counsel legal support and corporate governance advice for a variety of private and public sector organizations. Mr. Odynski currently serves on the Board of Directors of Serenic Corporation. At Ogilvie, his practice areas include health care, research and advanced technology.
Within healthcare specifically, Mr. Odynski has advised Alberta Innovates - Health Solutions as well as its predecessor, the Alberta Heritage Foundation for Medical Research. He served the Kidney Foundation of Canada as Alberta president, national vice president and member of the National Medical Advisory Committee and in 1979 was a recipient of the National President’s Award, which is granted to individuals or groups demonstrating outstanding contribution and dedication to the Kidney Foundation. ■
LATEST MOVES FROM Edmonton, AB, Canada – Fedora Pharmaceuticals, Inc., a private biotechnology company, announced the creation of a board of directors and the appointments of Leonard E. Post and Ronald W. Odynski as directors. [break]